Progress in gene therapy using oncolytic vaccinia virus as vectors

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Vaccinia virus (VACV) was integral to smallpox eradication and is now a promising gene therapy vector.
• VACV exhibits selective oncolytic activity, replicating productively within tumor cells.
• Key characteristics include rapid viral production, broad host range, large genome, and safe handling.

Purpose of the Study:

• To review vaccinia virus mechanisms, medical research, and clinical trials.
• To identify and discuss challenges in VACV-based gene therapy and cancer vaccines.
• To provide a theoretical basis for clinical treatment by addressing current problems.

Main Methods:

• Review of current research and experimental findings on vaccinia virus.
• Analysis of challenges in optimizing foreign gene selection for VACV vectors.
• Examination of administration and modification strategies for VACV in personalized medicine.

Main Results:

• Vaccinia virus demonstrates significant potential as an oncolytic agent and gene therapy vector.
• Identified challenges include optimal gene selection, VACV administration, and personalized medicine approaches.
• Current research highlights the need for further investigation into VACV mechanisms and clinical applications.

Conclusions:

• Solutions to identified problems will enhance understanding of VACV mechanisms.
• This review provides a theoretical foundation for advancing VACV in clinical settings.
• Further research is crucial for realizing the full therapeutic potential of vaccinia virus in cancer treatment.